Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device

OBJECTIVES: The CoV2-001 phase I randomized trial evaluated the safety and immunogenicity of the GLS-5310 bi-cistronic DNA vaccine through 48 weeks of follow-up. DESIGN: A total of 45 vaccine-naïve participants were recruited between December 31, 2020, and March 30, 2021. GLS-5310, encoding for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Woo Joo, Roberts, Christine C., Song, Joon Young, Yoon, Jin Gu, Seong, Hye, Hyun, Hak-Jun, Lee, Hyojin, Gil, Areum, Oh, Yeeun, Park, Ji-eun, Jeon, Bohyun, Lee, Ji-Eun, Choi, Sang Kyu, Yoon, Sun Kyung, Lee, Sunhee, Kim, Byoungguk, Kane, Deborah, Spruill, Susan, Kudchodkar, Sagar B., Muthumani, Kar, Park, Young K., Kwon, Ijoo, Jeong, Moonsup, Maslow, Joel N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803371/
https://www.ncbi.nlm.nih.gov/pubmed/36592685
http://dx.doi.org/10.1016/j.ijid.2022.12.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803371/
https://www.ncbi.nlm.nih.gov/pubmed/36592685
http://dx.doi.org/10.1016/j.ijid.2022.12.037

Ejemplares similares